肝硬変治療薬の世界市場インサイト・予測(~2025年)

QYResearchが発行した調査報告書(QYR20FB10630)
◆英語タイトル:Global Liver Cirrhosis Therapeutics Drugs Market Insights, Forecast to 2025
◆商品コード:QYR20FB10630
◆発行会社(リサーチ会社):QYResearch
◆発行日:2019年12月18日(※2024年版があります。お問い合わせください。)
◆ページ数:148
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

※本調査レポートでは、世界の肝硬変治療薬市場について調査・分析し、以下の構成でお届け致します。肝硬変治療薬の種類別には、経口、注射に、用途別には、病院、診療所、その他に、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。

・調査販売
・エグゼクティブ・サマリー
・企業別肝硬変治療薬売上データ
・地域別肝硬変治療薬市場規模:北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他
・種類別肝硬変治療薬市場規模:経口、注射
・用途別肝硬変治療薬市場規模:病院、診療所、その他
・主要メーカーの企業情報:Gilead Sciences、GlaxoSmithKline、Johnson & Johnson、Merck、Roche、Bristol-Myers Squibb、Conatus Pharmaceuticals、Gwo Xi Stem Cell Applied Technology、Instituto Grifols、Intercept Pharmaceuticals、NGM Biopharmaceuticals、Norgine、Pharmicell、Salix Pharmaceuticals、Stempeutics Research
・肝硬変治療薬の市場規模予測
・バリューチェーン及び販売チャネル分析
・市場機会・課題・リスク・影響因子分析
...
【レポートの概要】

The global Liver Cirrhosis Therapeutics Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Liver Cirrhosis Therapeutics Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Liver Cirrhosis Therapeutics Drugs in key regions like North America, Europe, China and Japan, focuses on the consumption of Liver Cirrhosis Therapeutics Drugs in these regions.
This research report categorizes the global Liver Cirrhosis Therapeutics Drugs market by top players/brands, region, type and end user. This report also studies the global Liver Cirrhosis Therapeutics Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Roche
Bristol-Myers Squibb
Conatus Pharmaceuticals
Gwo Xi Stem Cell Applied Technology
Instituto Grifols
Intercept Pharmaceuticals
NGM Biopharmaceuticals
Norgine
Pharmicell
Salix Pharmaceuticals
Stempeutics Research

Liver Cirrhosis Therapeutics Drugs market size by Type
Oral
Injection

Liver Cirrhosis Therapeutics Drugs market size by Applications
Hospitals
Clinics
Other

Market size by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Central & South America
Brazil
Middle East & Africa
Turkey
GCC Countries
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Liver Cirrhosis Therapeutics Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Liver Cirrhosis Therapeutics Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Liver Cirrhosis Therapeutics Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Liver Cirrhosis Therapeutics Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Liver Cirrhosis Therapeutics Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Liver Cirrhosis Therapeutics Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Study Coverage
1.1 Liver Cirrhosis Therapeutics Drugs Product Introduction
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Liver Cirrhosis Therapeutics Drugs Market Size Growth Rate by Type
1.4.2 Oral
1.4.3 Injection
1.5 Market by Application
1.5.1 Global Liver Cirrhosis Therapeutics Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Liver Cirrhosis Therapeutics Drugs Market Size
2.1.1 Global Liver Cirrhosis Therapeutics Drugs Revenue 2014-2025
2.1.2 Global Liver Cirrhosis Therapeutics Drugs Sales 2014-2025
2.2 Liver Cirrhosis Therapeutics Drugs Growth Rate by Regions
2.2.1 Global Liver Cirrhosis Therapeutics Drugs Sales by Regions
2.2.2 Global Liver Cirrhosis Therapeutics Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Liver Cirrhosis Therapeutics Drugs Sales by Manufacturers
3.1.1 Liver Cirrhosis Therapeutics Drugs Sales by Manufacturers
3.1.2 Liver Cirrhosis Therapeutics Drugs Sales Market Share by Manufacturers
3.2 Liver Cirrhosis Therapeutics Drugs Revenue by Manufacturers
3.2.1 Liver Cirrhosis Therapeutics Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Liver Cirrhosis Therapeutics Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Liver Cirrhosis Therapeutics Drugs Price by Manufacturers
3.4 Liver Cirrhosis Therapeutics Drugs Manufacturing Base Distribution, Product Types
3.4.1 Liver Cirrhosis Therapeutics Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Liver Cirrhosis Therapeutics Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Liver Cirrhosis Therapeutics Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
4.1 Global Liver Cirrhosis Therapeutics Drugs Sales by Type
4.2 Global Liver Cirrhosis Therapeutics Drugs Revenue by Type
4.3 Liver Cirrhosis Therapeutics Drugs Price by Type

5 Breakdown Data by Application
5.1 Overview
5.2 Global Liver Cirrhosis Therapeutics Drugs Breakdown Data by Application

6 North America
6.1 North America Liver Cirrhosis Therapeutics Drugs by Country
6.1.1 North America Liver Cirrhosis Therapeutics Drugs Sales by Country
6.1.2 North America Liver Cirrhosis Therapeutics Drugs Revenue by Country
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Liver Cirrhosis Therapeutics Drugs by Type
6.3 North America Liver Cirrhosis Therapeutics Drugs by Application

7 Europe
7.1 Europe Liver Cirrhosis Therapeutics Drugs by Country
7.1.1 Europe Liver Cirrhosis Therapeutics Drugs Sales by Country
7.1.2 Europe Liver Cirrhosis Therapeutics Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Liver Cirrhosis Therapeutics Drugs by Type
7.3 Europe Liver Cirrhosis Therapeutics Drugs by Application

8 Asia Pacific
8.1 Asia Pacific Liver Cirrhosis Therapeutics Drugs by Region
8.1.1 Asia Pacific Liver Cirrhosis Therapeutics Drugs Sales by Region
8.1.2 Asia Pacific Liver Cirrhosis Therapeutics Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Thailand
8.1.10 Malaysia
8.1.11 Philippines
8.1.12 Vietnam
8.2 Asia Pacific Liver Cirrhosis Therapeutics Drugs by Type
8.3 Asia Pacific Liver Cirrhosis Therapeutics Drugs by Application

9 Central & South America
9.1 Central & South America Liver Cirrhosis Therapeutics Drugs by Country
9.1.1 Central & South America Liver Cirrhosis Therapeutics Drugs Sales by Country
9.1.2 Central & South America Liver Cirrhosis Therapeutics Drugs Revenue by Country
9.1.3 Brazil
9.2 Central & South America Liver Cirrhosis Therapeutics Drugs by Type
9.3 Central & South America Liver Cirrhosis Therapeutics Drugs by Application

10 Middle East and Africa
10.1 Middle East and Africa Liver Cirrhosis Therapeutics Drugs by Country
10.1.1 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Sales by Country
10.1.2 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Revenue by Country
10.1.3 Turkey
10.1.4 GCC Countries
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Liver Cirrhosis Therapeutics Drugs by Type
10.3 Middle East and Africa Liver Cirrhosis Therapeutics Drugs by Application

11 Company Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Details
11.1.2 Company Business Overview
11.1.3 Gilead Sciences Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Gilead Sciences Liver Cirrhosis Therapeutics Drugs Products Offered
11.1.5 Gilead Sciences Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 Company Business Overview
11.2.3 GlaxoSmithKline Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 GlaxoSmithKline Liver Cirrhosis Therapeutics Drugs Products Offered
11.2.5 GlaxoSmithKline Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Company Business Overview
11.3.3 Johnson & Johnson Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Johnson & Johnson Liver Cirrhosis Therapeutics Drugs Products Offered
11.3.5 Johnson & Johnson Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Company Business Overview
11.4.3 Merck Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Merck Liver Cirrhosis Therapeutics Drugs Products Offered
11.4.5 Merck Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Company Business Overview
11.5.3 Roche Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Roche Liver Cirrhosis Therapeutics Drugs Products Offered
11.5.5 Roche Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Company Business Overview
11.6.3 Bristol-Myers Squibb Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Bristol-Myers Squibb Liver Cirrhosis Therapeutics Drugs Products Offered
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Conatus Pharmaceuticals
11.7.1 Conatus Pharmaceuticals Company Details
11.7.2 Company Business Overview
11.7.3 Conatus Pharmaceuticals Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Conatus Pharmaceuticals Liver Cirrhosis Therapeutics Drugs Products Offered
11.7.5 Conatus Pharmaceuticals Recent Development
11.8 Gwo Xi Stem Cell Applied Technology
11.8.1 Gwo Xi Stem Cell Applied Technology Company Details
11.8.2 Company Business Overview
11.8.3 Gwo Xi Stem Cell Applied Technology Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Gwo Xi Stem Cell Applied Technology Liver Cirrhosis Therapeutics Drugs Products Offered
11.8.5 Gwo Xi Stem Cell Applied Technology Recent Development
11.9 Instituto Grifols
11.9.1 Instituto Grifols Company Details
11.9.2 Company Business Overview
11.9.3 Instituto Grifols Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Instituto Grifols Liver Cirrhosis Therapeutics Drugs Products Offered
11.9.5 Instituto Grifols Recent Development
11.10 Intercept Pharmaceuticals
11.10.1 Intercept Pharmaceuticals Company Details
11.10.2 Company Business Overview
11.10.3 Intercept Pharmaceuticals Liver Cirrhosis Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Intercept Pharmaceuticals Liver Cirrhosis Therapeutics Drugs Products Offered
11.10.5 Intercept Pharmaceuticals Recent Development
11.11 NGM Biopharmaceuticals
11.12 Norgine
11.13 Pharmicell
11.14 Salix Pharmaceuticals
11.15 Stempeutics Research

12 Future Forecast
12.1 Liver Cirrhosis Therapeutics Drugs Market Forecast by Regions
12.1.1 Global Liver Cirrhosis Therapeutics Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global Liver Cirrhosis Therapeutics Drugs Revenue Forecast by Regions 2019-2025
12.2 Liver Cirrhosis Therapeutics Drugs Market Forecast by Type
12.2.1 Global Liver Cirrhosis Therapeutics Drugs Sales Forecast by Type 2019-2025
12.2.2 Global Liver Cirrhosis Therapeutics Drugs Revenue Forecast by Type 2019-2025
12.3 Liver Cirrhosis Therapeutics Drugs Market Forecast by Application
12.4 North America Liver Cirrhosis Therapeutics Drugs Forecast
12.5 Europe Liver Cirrhosis Therapeutics Drugs Forecast
12.6 Asia Pacific Liver Cirrhosis Therapeutics Drugs Forecast
12.7 Central & South America Liver Cirrhosis Therapeutics Drugs Forecast
12.8 Middle East and Africa Liver Cirrhosis Therapeutics Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Liver Cirrhosis Therapeutics Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

...

【掲載企業】

Gilead Sciences、GlaxoSmithKline、Johnson & Johnson、Merck、Roche、Bristol-Myers Squibb、Conatus Pharmaceuticals、Gwo Xi Stem Cell Applied Technology、Instituto Grifols、Intercept Pharmaceuticals、NGM Biopharmaceuticals、Norgine、Pharmicell、Salix Pharmaceuticals、Stempeutics Research

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肝硬変治療薬の世界市場インサイト・予測(~2025年)(Global Liver Cirrhosis Therapeutics Drugs Market Insights, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。